

4 June 2024

**Deltex Medical Group plc**  
("Deltex Medical" or the "Group")

**Deltex's new TrueVue System awarded to an NHS Supply Chain Framework Agreement**

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, is pleased to announce the successful award by NHS Supply Chain ("NHSSC") of the national framework tender for the new TrueVue System in the UK. The award means that the new TrueVue System has been selected by NHSSC as a pre-approved device that can be purchased by NHS hospitals.

**Commenting on the award, Andy Mears, CEO of Deltex Medical, said:**

*"We are delighted to have been awarded this framework agreement and in particular, with NHSSC seeing the value of the new TrueVue System to the NHS. Being selected to participate in the framework agreement with the NHSSC makes it easier for NHS hospitals to access the benefits of TrueVue including better surgical outcomes, significantly fewer post-operative complications and reduced hospital length of stay"*

The framework agreement is not a purchase order but enables the NHS and approved customers to purchase Deltex Medical's new TrueVue System through a compliant route to market. The new TrueVue System will be supplied under NHSSC product category "lot 2: Specialist Patient Monitoring Equipment". This product category sits within the Patient Monitoring Equipment, Bedside Equipment Alarm Monitoring System and Related Products and Services category.

The framework agreement will commence on 8 June 2024 and, subject to the terms and conditions of the agreement, runs for a minimum of 24 months with an option for it to be extended by up to another 24 months.

The role of NHSSC is to source, deliver and supply healthcare products, services and food for NHS trusts and healthcare organisations across England and Wales. The tender award process for the new TrueVue System consisted of six steps in total, which were as follows:

- Initial review of tender contents
- Qualification
- Product Compliance
- Evaluation of non-financial information
- Evaluation of financial information
- Calculation of final scores and award of framework agreement

The new TrueVue System is the only haemodynamic monitor that combines direct independent measurements of both blood flow and blood pressure in a patient across each and every heartbeat in real time, providing the clinician with a range of clinically validated haemodynamic parameters. These haemodynamic parameters are used by clinicians to assess the patient's cardiac function to guide fluid and drug therapy to optimise cardiovascular performance (heart contractility) or normalise circulating blood volume (normovolaemia).

For further information, please contact:

**Deltex Medical Group plc**

Nigel Keen, Chairman

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

01243 774 837

[investorinfo@Deltexmedical.com](mailto:investorinfo@Deltexmedical.com)

**Allenby Capital Limited - Nominated Adviser & Broker**

020 3328 5656

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

[info@allenbycapital.com](mailto:info@allenbycapital.com)

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)